BlackRock
VVOS icon

BlackRock’s Vivos Therapeutics VVOS Stock Holding History

BlackRock’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.8K Hold
27,817
– – ﹤0.01% 5213
2025
Q4 		$56.5K Hold
27,817
– – ﹤0.01% 5024
2025
Q3 		$86.2K Buy
+27,817
New +$126K ﹤0.01% 4865
2024
Q1 		– Sell
-42
Closed -$522 – 5405
2023
Q4 		$522 Buy
42
+1
+2% +$9 ﹤0.01% 5287
2023
Q3 		$199 Sell
41
-52
-56% -$393 ﹤0.01% 5381
2023
Q2 		$1.19K Sell
93
-1,853
-95% -$18.1K ﹤0.01% 5394
2023
Q1 		$16.6K Buy
1,946
+62
+3% +$1.36K ﹤0.01% 5275
2022
Q4 		$18.9K Buy
1,884
+41
+2% +$600 ﹤0.01% 5385
2022
Q3 		$30K Sell
1,843
-52
-3% -$1.58K ﹤0.01% 5452
2022
Q2 		$60K Sell
1,895
-30
-2% -$1.25K ﹤0.01% 5376
2022
Q1 		$129K Sell
1,925
-93
-5% -$6.08K ﹤0.01% 5229
2021
Q4 		$114K Buy
2,018
+62
+3% +$4.99K ﹤0.01% 5232
2021
Q3 		$198K Buy
1,956
+1,406
+256% +$148K ﹤0.01% 4993
2021
Q2 		$68K Buy
550
+88
+19% +$14.3K ﹤0.01% 5138
2021
Q1 		$77K Buy
+462
New +$82.5K ﹤0.01% 4867

Other funds holding VVOS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock's VVOS Position: Q1 2026 in Review

BlackRock held its Vivos Therapeutics (VVOS) position steady in Q1 2026 at 27,817 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5213.

BlackRock first reported a position in VVOS in Q1 2021 and has held it in 15 quarters since. The position peaked at $198K in Q3 2021. 24 funds tracked by Wall St. Rank hold VVOS as of Q1 2026.

  • BlackRock held 27,817 shares of Vivos Therapeutics worth $32.8K as of Q1 2026.
  • BlackRock left its Vivos Therapeutics share count unchanged in Q1 2026.
  • Vivos Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5213 holding.
  • BlackRock first reported a position in Vivos Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • BlackRock's Vivos Therapeutics position peaked at $198K in Q3 2021.
  • 24 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.